(Q28289064)
Statements
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis (English)
0 references
November 2004
0 references
64
0 references
2
0 references
103-11
0 references